tot biopharm-小9直播体育免费直播下载ios

• making recommendations to the board on the appointment, reappointment and removal of external auditors, approving the remuneration and terms of engagement of external auditors, and dealing with any issues in relation to resignation or dismissal of external auditors；

• reviewing and monitoring external auditors’ independence and objectivity and the effectiveness of the audit process in accordance with applicable standards, discussing with auditors on the nature and scope of the audit work and reporting obligations before the audit commences;

• developing and implementing policies with respect to the non-audit work provided by external auditors;

• examining the completeness of the group’s financial statements and the group’s quarterly, interim and annual reports, and reviewing critical   financial reporting judgments contained therein;

• overseeing the group’s financial reporting, risk management and internal control systems;

• managing matters related to connected transactions;

• reviewing and approving the group’s connected transactions and other related matters to the extent authorized by the board;

• formulating, monitoring and overseeing the anti-corruption and anti-bribery policies and systems of the group;

• formulating, monitoring and overseeing the whistle-blowing policies and systems of the group; and

• providing information for the independent non-executive directors and auditors to perform their annual review of the connected transactions

• making recommendations to the board on the compensation remuneration packages of individual executive directors and senior management and on the compensation of non-executive director;

• making recommendations to the board on the management’s remuneration proposals;

• ensuring that no director or any of his/her associates is involved in deciding his/her own remuneration;

• developing policies and structure for remuneration of all directors, senior management and employees including salaries, incentive schemes and other share schemes, and making recommendations to the board; and

• reviewing and/or approving matters relating to share schemes under chapter 17 of the listing rules, including any grants of options or awards to directors, senior management, consultants and employees and making disclosure and giving explanation on the appropriateness to such material matters (if any) being approved in the corporate governance report.

• reviewing the structure, size and composition of the board at least annually and making recommendations on any proposed changes to the board to complement the company’s corporate strategy;

• identifying individuals suitably qualified to become board members and making recommendations to the board;

• assessing the independence of independent non-executive directors;

• making recommendations to the board on the appointment and succession planning of directors

• reviewing the diversification policy and its implementation on an annual basis, developing and reviewing measurable objectives for implementing the diversification policy and monitoring the progress on achieving these objectives;

• formulating and reviewing the policy for the nomination of directors which includes the nomination process and the criteria;

• formulating and reviewing on an annual basis the mechanism to ensure independent views and inputs are available to the board; and

• reviewing and monitoring the training and continuous professional development of directors, coordinating with the company for arranging appropriate trainings with appropriate focus on the roles, functions and responsibilities of director.

• reviewing and making recommendations to the board on the long-term strategic development plans of the company;

• reviewing and making recommendations to the board in relation to any significant capital operations (including but not limited to the alternation of the registered issued share capital; issuance of bonds or other securities; the merger, separation, dissolution or transformation of company structure of the company or any of its wholly owned or holding subsidiaries; the company’s profit distribution plan and plans for loss recovery), asset management projects, the company’s annual financial budget plan, and final accounts;

• reviewing and making recommendations to the board on any financing investment projects relating to issuance of securities by the company or any of its wholly owned or holding subsidiaries;

• reviewing the group’s major investment and financing proposals in accordance with the amended and restated articles of association and overseas investment management measures, and making recommendations to the board;

• making recommendations to the board on any major matters that would affect the company’s development;

• implementing and supervising the above items, reviewing, evaluating and making recommendations on any major changes made to these items, for the board’s approval;

• developing the company’s esg objectives, strategies and structure, reviewing the progress in achieving the company’s esg objectives, and making recommendations to the board on relevant esg work in line with the company’s strategic development;

• reviewing esg-related issues that have a significant impact on the company’s operations and/or the interests of other key stakeholders;

• considering the company’s assessment of its environmental and social impact, and reviewing international and china’s esg trends, in order to ensure the effective assessment of potential impact, opportunities and risks to the company’s business;

• monitoring the implementation of the company’s esg policies and strengthening process control to ensure that the sustainability and effectiveness of the relevant actions in compliance with applicable laws and regulatory requirements;

• referring to key esg reporting guidance for the relevant industry or sector, and to widely consider suggestions from stakeholders or to seek independent assurance verification by third parties in order to strengthen the scientific management of esg and the credibility of esg information disclosure;

• making timely, accurately and complete information disclosure under the requirements of the listing rules, the cg code (set out in appendix 14 to the listing rules) and the environmental, social and governance reporting guide (set out in appendix 27 to the listing rules); and

• other matters authorized by the board.

dr. liu, jun (劉軍), ceo

dr. liu, jun (劉軍博士),aged 55, joined the group on 17 october 2016 and was appointed as an executive director, chief scientific officer and chief executive officer on 26 october 2018, 12 march 2019 and 15 october 2020, respectively. he is also a member of the strategy and esg committee. dr. liu, jun served as vice general manager of the company between 17 october 2016 and 15 october 2020, and as chief operating officer of the company between 21 april 2020 and 15 october 2020. he is currently fully responsible for the operation and management of the group, including research and development, operations management and business development, among others.

prior to joining the group, dr. liu, jun was the executive director of biologics research and development department in shanghai chempartner co., ltd. between july 2010 and october 2016. prior to that, he was employed by bayer us llc between april 2005 and july 2010 working with bayer healthcare as a senior scientist in the united states.

dr. liu, jun obtained a ph.d. in bioanalytical chemistry from the university of california, davis in the united states in december 2002 and a bachelor’s degree in chemistry from the university of science & technology of china in hefei, anhui province, the prc in july 1991.

mr. fu, shan（chairperson of the board）

mr. fu, shan (付山先生), aged 55, joined the group on 19 january 2016 as a non-executive director and was appointed the chairperson of the board on 28 september 2018. he is also the chairperson of the nomination committee and the strategy and esg committee. he has previously used the chinese name “fu shan (傅山)”.

mr. fu has since october 2013 been a managing partner, a co-ceo and the greater china ceo of vivo capital llc, which is an investment management firm that primarily invests in the field of biotechnology and healthcare. between june 2008 and october 2013, mr. fu worked as a senior managing director in the beijing branch of blackstone (shanghai) equity investment management company limited. he has been a non-executive director of lepu scientech medical technology (shanghai) co., ltd. (hong kong stock exchange: 2291) since june 2021, a director of sinovac biotech ltd. (nasdaq: sva) since july 2018, and a director of genetron holdings limited (nasdaq: gth) since june 2021. he was also a nonexecutive director of innocare pharma limited (hong kong stock exchange: 9969) from february 2018 to march 2023.

mr. fu obtained a master’s degree in history and a bachelor’s degree in history, both from peking university in beijing, the prc, in july 1991 and july 1988, respectively. 

ms. yeh-huang, chun-ying (vice chairperson of the board)

ms. yeh-huang, chun-ying (黃純瑩女士), aged 64, joined the group on 5 july 2010 and was appointed as the vice chairperson of the board on 15 october 2020. she is also a member of the strategy and esg committee. ms. yeh-huang served as the general manager of the group between 5 july 2010 and 15 october 2020. ms. yeh-huang was re-designated from an executive director to a nonexecutive director of the company with effect from 1 january 2023 and has been responsible for the oversight of strategy formulation and development of the group.

from april 1986 to december 2015, ms. yeh-huang worked at tty biopharm company limited, during which she became an executive vice president of the oncology science business development unit in april 2011. as the head of tty biopharm company limited’s oncology science business development unit, she was responsible for product development, clinical research, marketing and sales. she also managed cancer translation centers and medical academies and was responsible for the expansion of oncology science business market construction and team management in china and vietnam. she was a pharmacist of taipei veterans general hospital from july 1983 to august 1985.

ms. yeh-huang obtained a bachelor’s degree in pharmacy from taipei medical college (now known as taipei medical university) in taiwan in june 1982 and obtained her taiwan license of pharmacist in june 1983.

dr. liu, weidong

dr. liu, weidong (劉衛東博士)，aged 55, has been appointed as a non-executive director of the company, the chairperson of the remuneration committee and a member of each of the audit and connected transactions review committee and the strategy and esg committee, all with effect from 12 august 2023. dr. liu, weidong will also be appointed as a director of tot suzhou in due course.

dr. liu, weidong possesses extensive experience in pharmaceutical process research and development as well as cmc (chemistry, manufacturing and controls) management. he obtained a bachelor’s degree and a master’s degree in chemistry from peking university (北京大學) in china in 1989 and 1994, respectively, and obtained a ph.d. in organic chemistry from the university of pittsburgh in the united states in 2000. he worked at array biopharma inc. (formerly nasdaq: arry; now part of pfizer inc. (new york stock exchange: pfe)) from october 2001 to may 2015 with his last position as principal research investigator of process chemistry. he then worked at avista pharma solutions (now part of cambrex corporation (formerly new york stock exchange: cbm)) from june 2015 to february 2016 as director of process chemistry, and at changzhou sta pharmaceutical r&d co., ltd. (常州合全新藥研發有限公司) (a subsidiary of wuxi apptec co., ltd. (無錫藥明康德新藥開發股份有限公司) (hong kong stock exchange: 2359; shanghai stock exchange: 603259)) from march 2016 to april 2017 as executive director of process research and development.

dr. liu, weidong joined vivo capital llc, a substantial shareholder of the company, in august 2017 and is currently serving as managing director. he served as a director of genetron holdings limited (nasdaq: gth) between november 2019 and june 2021.

ms. hu, lan

ms. hu, lan (胡蘭女士), aged 51, joined the group on 12 march 2019 as an independent non-executive director. she is also the chairperson of the audit and connected transactions review committee, and a member of the nomination committee.

ms. hu has more than 20 years of experience working at international accounting firms, through which she has gained accounting and financial management expertise. ms. hu was a partner of the consulting services department of pricewaterhousecoopers between july 2008 and june 2018. during this period, she led financial due diligence projects for corporate and financial buyers, with a focus on analyzing the financial statements, reviewing the profit forecasts and reviewing the internal control reports of target companies. prior to that, she worked at pricewaterhousecoopers from july 2002, and previously at arthur andersen from july 1994. during these periods, she served as a public accountant and was responsible for auditing and reviewing the financial statements of listing applicants and listed companies. she has been an independent non-executive director of innocare pharma limited (hong kong stock exchange: 9969) since march 2020.

ms. hu obtained an mba degree from university at buffalo, the state university of new york in the united states in february 2005 and a bachelor’s degree in accounting from beijing machinery and industrial institute in beijing, the prc in july 1994. she gained her chinese institute of certified public accountants qualification in march 1997.

mr. chang, hong-jen

mr. chang, hong-jen (張鴻仁先生),  aged 66, joined the group on 12 march 2019 as an independent non-executive director. he is also a member of the audit and connected transactions review committee and the remuneration committee. he has over 15 years of experience in biotech investment.

mr. chang has served as an adjunct professor of institute of public health, national yang-ming university from august 2005, the chairman of yfy biotech management co., ltd. from july 2005, the chairman of micareo taiwan co., ltd. from july 2011, and the chairman of eusol biotech co., ltd. (taipei exchange: 6652) from october 2009. he has been a director of excelsior biopharma inc. (taipei exchange: 6496) from june 2015, a director of taigen biopharmaceuticals holdings limited (taipei exchange: 4157) from april 2013, a director of medeon biodesign, inc. (taipei exchange: 6499) from july 2018, and a director of formosa pharmaceuticals inc. (taipei exchange: 6838) from june 2020. he was also a director of taiwan liposome company ltd. (formerly taipei exchange:4152) from june 2007 to june 2019.mr. chang worked in the department of health of taiwan’s executive yuan from february 2001 to november 2004, where his last position held was as the deputy minister.

mr. chang obtained his bachelor’s degree in medicine from national yang-ming medical college in taiwan in june 1982, master’s degree in public health from national taiwan university in taiwan in june 1984, and master’s degree in health services administration from harvard university in the united states in june 1987.

dr. wang, de qian

dr. wang, de qian (汪德潛博士), aged 72, joined the group on 12 march 2022 as an independent non-executive director. he is also a member of the remuneration committee, the nomination committee and the strategy and esg committee. he served multiple positions under the bayer ag (frankfurt stock exchange: bayn) group between 1994 and 2016, and served as vice president of a subsidiary of wuxi biologics (cayman) inc. (hong kong stock exchange:2269) between 2016 and 2021.

dr. wang possesses extensive experience in the area of biopharmacy. he obtained a bachelor’s degree in agricultural machinery from liaoning agricultural college (now known as shenyang agricultural university) in china in 1977, and obtained a master’s degree in bioresource engineering and a ph.d. in mechanical engineering (bioengineering) from oregon state university in the united states in 1987 and 1991, respectively.